Meet Dr. Dafna Bar-Sagi: Chief Scientific Officer at NYU Langone | NYU Langone Health
View a video of Dr. Dafna Bar-Sagi, NYU Langone’s chief scientific officer, to learn why she’s optimistic about curing cancer.
Meet Dr. Francis Arena: Medical Oncologist | NYU Langone Health
Watch a video of Perlmutter Cancer Center medical oncologist Dr. Francis Arena on how we now have the tools to personalize cancer treatment.
Meet Dr. Jiyoung Ahn: Associate Director, Population Sciences | NYU Langone Health
Watch a video of Perlmutter Cancer Center researcher Dr. Jiyoung Ahn discussing how prevention is the best cure for cancer.
Meet Dr. Richard Shapiro: Surgical Oncologist, Breast and Skin Cancer | NYU Langone Health
Watch a video of Perlmutter Cancer Center surgical oncologist Dr. Richard Shapiro, and find out about his personal experience with melanoma.
Meet Our Leadership Team | NYU Langone Health
NYU Langone Orthopedic Center is led by an experienced team of healthcare experts.
Meet Our Pediatric Gastroenterology Team | NYU Langone Health
NYU Langone’s Pediatric Gastroenterology Program includes nurses, child life specialists, and social workers who support your child.
Meet Our Team | NYU Langone Health
Meet the team at NYU Langone’s Cochlear Implant Center, including surgeons and audiologists who specialize in all types of hearing loss.
Meet Phil and Paul: Prostate Cancer Survivors | NYU Langone Health
When Phil and Paul Malenczak were diagnosed with prostate cancer, they sought advanced treatment at NYU Langone’s Perlmutter Cancer Center.
Melanoma | NYU Langone Health
At NYU Langone’s Perlmutter Cancer Center, dermatologists, oncologists, surgeons, and radiation oncologists diagnose and treat melanoma.
Melanoma Margins Trial (MelMarT): A Phase III Multi-Centre Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma.
You can participate in this study if you are diagnosed with skin melanoma stage 2. This study will determine whether there is a difference in disease free survival for patients treated with either a 1cm excision margin or 2cm margin for clinical stage II, primary skin melanoma. The study is designed to be able to prove or disprove that there is no difference in risk of melanoma recurrence between the two groups of patients. This study is designed to show that the risk of long-term pain associated with surgery can be reduced.A 1cm excision margin will reduce the risk of long-term pain and will reduce surgical complication rates. A 1cm excision margin will have an impact on improved quality of life for patients and change the use of local healthcare resources. Once determined as being eligible, patients will be randomized 1:1 to either a 1 cm excision margin or a 2 cm excision margin, in combination with a staging sentinel lymph node (the first lymph node to which cancer cells are most likely to spread from a primary tumor).